DAWN vs. AVDL, DVAX, PCRX, MORF, AKRO, ANIP, KNSA, GMTX, LGND, and GYRE
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Avadel Pharmaceuticals (AVDL), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), Morphic (MORF), Akero Therapeutics (AKRO), ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical preparations" industry.
Day One Biopharmaceuticals (NASDAQ:DAWN) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
Avadel Pharmaceuticals has higher revenue and earnings than Day One Biopharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Day One Biopharmaceuticals has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -284.42%. Day One Biopharmaceuticals' return on equity of -57.28% beat Avadel Pharmaceuticals' return on equity.
Avadel Pharmaceuticals received 298 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 65.22% of users gave Avadel Pharmaceuticals an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.
Day One Biopharmaceuticals has a beta of -1.44, suggesting that its stock price is 244% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
In the previous week, Avadel Pharmaceuticals had 5 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 15 mentions for Avadel Pharmaceuticals and 10 mentions for Day One Biopharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 0.54 beat Day One Biopharmaceuticals' score of -0.09 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 8.4% of Day One Biopharmaceuticals shares are held by insiders. Comparatively, 4.0% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Day One Biopharmaceuticals currently has a consensus price target of $37.67, indicating a potential upside of 132.94%. Avadel Pharmaceuticals has a consensus price target of $24.17, indicating a potential upside of 56.01%. Given Day One Biopharmaceuticals' higher probable upside, research analysts plainly believe Day One Biopharmaceuticals is more favorable than Avadel Pharmaceuticals.
Summary
Avadel Pharmaceuticals beats Day One Biopharmaceuticals on 9 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
